HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5'- ((N- (2- decanoylamino- 3- hydroxy- 3- phenylpropyloxycarbonyl)glycyl)amino)- 5'- deoxyuridine (PP36)

inhibits various membrane-associated UDP-glycosyltransferases; structure given in first source

Also Known As:

PP36; PP 36; PP-36

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidine Nucleosides: 50
      - Uridine: 1186
        Deoxyuridine: 331
        5'-((N-(2-decanoylamino-3-hydroxy-3-phenylpropyloxycarbonyl)glycyl)amino)-5'-deoxyuridine: 5
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Pyrimidine Nucleosides: 50
    - Uridine: 1186
      - Deoxyuridine: 331
        5'-((N-(2-decanoylamino-3-hydroxy-3-phenylpropyloxycarbonyl)glycyl)amino)-5'-deoxyuridine: 5
  - Deoxyribonucleosides: 34
    - Deoxyuridine: 331
      - 5'-((N-(2-decanoylamino-3-hydroxy-3-phenylpropyloxycarbonyl)glycyl)amino)-5'-deoxyuridine: 5
Organic Chemicals: 133
- Amines: 4871
  - Amino Alcohols: 20
    - Propanolamines: 4
      - 5'-((N-(2-decanoylamino-3-hydroxy-3-phenylpropyloxycarbonyl)glycyl)amino)-5'-deoxyuridine: 5
- Alcohols: 595
  - Amino Alcohols: 20
    - Propanolamines: 4
      - 5'-((N-(2-decanoylamino-3-hydroxy-3-phenylpropyloxycarbonyl)glycyl)amino)-5'-deoxyuridine: 5
  - Propanols: 3
    - Propanolamines: 4
      - 5'-((N-(2-decanoylamino-3-hydroxy-3-phenylpropyloxycarbonyl)glycyl)amino)-5'-deoxyuridine: 5

Experts

1.	Aboussekhra, Abdelilah: 1 article (04/2012)
2.	Al-Qasem, Abeer: 1 article (04/2012)
3.	Al-Tweigeri, Taher: 1 article (04/2012)
4.	Elkum, Naser: 1 article (04/2012)
5.	Toulimat, Mohamed: 1 article (04/2012)
6.	Tulbah, Asma: 1 article (04/2012)
7.	Bansal, Jyotika: 1 article (01/2010)
8.	Bhatt, Lokesh K: 1 article (01/2010)
9.	Bodhankar, S L: 1 article (01/2010)
10.	Piplani, Poonam: 1 article (01/2010)

Related Diseases

1.	Myocardial Ischemia (Ischemic Heart Diseases) 10/01/2009 - "Previously we described the oral endothelin-converting enzyme (ECE) inhibitor, PP36, and in this study, we investigated its cardioprotective effect in more detail, and examined the role of PP36 in the neurohormonal activation in rats that had been subjected to acute myocardial ischemia due to the microsphere embolization of coronary microcirculation. "
2.	Coronary Occlusion 01/01/2010 - "Pre-ischemic administration (20 minutes before coronary occlusion) of PP-36 showed cardioprotective effects against ischemia/reperfusion injury in rats. "
3.	Reperfusion Injury 01/01/2010 - "Pre-ischemic administration (20 minutes before coronary occlusion) of PP-36 showed cardioprotective effects against ischemia/reperfusion injury in rats. " 01/01/2010 - "In conclusion, PP-36 is a β-adrenoceptor antagonist possessing potent anti-arrhythmic and cardioprotective effects against ischemia/reperfusion injury in rats. "
4.	Infarction (Infarctions) 01/01/2010 - "PP-36 (6 mg kg(-1)) significantly reduced arrhythmia score (6.33 ± 0.55, P < 0.05), infarct size/left ventricle size (38.9 ± 3.2, P < 0.05) and no mortality compared to vehicle-treated control group (14.17 ± 1.83, 44.9 ± 4.6 and 17% respectively). "
5.	Pulmonary Hypertension 07/01/2008 - "This data shows that treatment with endothelin-converting enzyme blocker PP36 significantly reduced pathological changes due to hypoxia-induced pulmonary hypertension. "

Related Drugs and Biologics

1.	Endothelin-Converting Enzymes
2.	Adrenergic Receptors (Adrenergic Receptor)
3.	Anti-Arrhythmia Agents
4.	prolyl-proline (Pro-Pro)
5.	arginylarginine (Arg-Arg)
6.	arginylproline

Related Therapies and Procedures

1.	Microspheres (Microsphere)